A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME
Background: Siglec-15 (S15) is a type-I transmembrane protein and is considered a new candidate of immune checkpoint inhibitor for cancer immunotherapy. Methods: In the present study, we first constructed and characterized a chimeric S15-specific monoclonal antibody (S15–4E6A). Then, the antitumor e...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-07-01
|
Series: | Pharmacological Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661822002146 |